These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 31011260)

  • 21. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
    Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
    Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
    [No Abstract]   [Full Text] [Related]  

  • 22. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease.
    Buisson A; Hordonneau C; Goutte M; Scanzi J; Goutorbe F; Klotz T; Boyer L; Pereira B; Bommelaer G
    Dig Liver Dis; 2016 Mar; 48(3):260-6. PubMed ID: 26699828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
    Rutgeerts P; Reinisch W; Colombel JF; Sandborn WJ; D'Haens G; Petersson J; Zhou Q; Iezzi A; Thakkar RB
    Gastrointest Endosc; 2016 Jan; 83(1):188-97.e1-3. PubMed ID: 26234693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
    Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
    Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-Invasive Assessment of Inflammation and Treatment Response in Patients with Crohn's Disease and Ulcerative Colitis using Contrast-Enhanced Ultrasonography Quantification.
    Socaciu M; Ciobanu L; Diaconu B; Hagiu C; Seicean A; Badea R
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):457-65. PubMed ID: 26697572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
    Verstockt B; Verstockt S; Creyns B; Tops S; Van Assche G; Gils A; Ceuppens JL; Vermeire S; Ferrante M; Breynaert C
    Aliment Pharmacol Ther; 2019 Mar; 49(5):572-581. PubMed ID: 30663072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.
    Volkers A; Bossuyt P; de Jong J; Pouillon L; Gecse K; Duijvestein M; Ponsioen C; D'Haens G; Löwenberg M
    Scand J Gastroenterol; 2022 Apr; 57(4):439-445. PubMed ID: 34968158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing.
    Eder P; Lykowska-Szuber L; Iwanik K; Krela-Kazmierczak I; Stawczyk-Eder K; Majewski P; Linke K; Kay EW; Wozniak A
    Folia Histochem Cytobiol; 2016; 54(2):75-80. PubMed ID: 27270504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.
    Dige A; Magnusson MK; Öhman L; Hvas CL; Kelsen J; Wick MJ; Agnholt J
    Scand J Gastroenterol; 2016; 51(6):692-9. PubMed ID: 26784676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
    Hébuterne X; Lémann M; Bouhnik Y; Dewit O; Dupas JL; Mross M; D'Haens G; Mitchev K; Ernault É; Vermeire S; Brixi-Benmansour H; Moreels TG; Mary JY; Marteau P; Colombel JF
    Gut; 2013 Feb; 62(2):201-8. PubMed ID: 22525883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.
    Beigel F; Deml M; Schnitzler F; Breiteneicher S; Göke B; Ochsenkühn T; Brand S
    PLoS One; 2014; 9(6):e99293. PubMed ID: 24932476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
    D'Haens G; Kelly O; Battat R; Silverberg MS; Laharie D; Louis E; Savarino E; Bodini G; Yarur A; Boland BS; Afif W; Li XJ; Hale M; Ho J; Kondragunta V; Huang B; Kuy C; Okada L; Hester KD; Bray KR; Mimms L; Jain A; Singh S; Collins A; Valasek MA; Sandborn WJ; Vermeire S; Dulai PS
    Gastroenterology; 2020 Feb; 158(3):515-526.e10. PubMed ID: 31711925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.